Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-Current DebtShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Cash from Operations: 2014-2025

Historic Cash from Operations for Ascendis Pharma A (ASND) over the last 12 years, with Sep 2025 value amounting to $2.5 million.

  • Ascendis Pharma A's Cash from Operations rose 104.08% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$114.0 million, marking a year-over-year increase of 59.82%. This contributed to the annual value of -$331.4 million for FY2024, which is 34.09% up from last year.
  • Latest data reveals that Ascendis Pharma A reported Cash from Operations of $2.5 million as of Q3 2025, which was up 130.29% from -$8.3 million recorded in Q2 2025.
  • In the past 5 years, Ascendis Pharma A's Cash from Operations registered a high of $2.5 million during Q3 2025, and its lowest value of -$166.7 million during Q2 2023.
  • In the last 3 years, Ascendis Pharma A's Cash from Operations had a median value of -$66.0 million in 2024 and averaged -$78.0 million.
  • As far as peak fluctuations go, Ascendis Pharma A's Cash from Operations crashed by 122.49% in 2021, and later spiked by 104.08% in 2025.
  • Over the past 5 years, Ascendis Pharma A's Cash from Operations (Quarterly) stood at -$143.4 million in 2021, then fell by 0.83% to -$144.6 million in 2022, then soared by 68.39% to -$45.7 million in 2023, then plummeted by 103.86% to -$93.2 million in 2024, then skyrocketed by 104.08% to $2.5 million in 2025.
  • Its Cash from Operations was $2.5 million in Q3 2025, compared to -$8.3 million in Q2 2025 and -$15.1 million in Q1 2025.